DECEMBER: De-escalation of CDK4/6 inhibitors for ER-positive, HER2-negative metastatic breast cancer in complete response
Sponsor: Unicancer
Phase: 3
Disease: Hormone receptor-positive, HER2-negative metastatic breast cancer, Locally advanced hormone receptor-positive, HER2-negative breast cancer
EU trial number: 2026-526319-12-00
Population: Adults with ER-positive, HER2-negative metastatic or locally advanced breast cancer who have achieved a complete response or partial response with sclerotic bone-only lesions for at least six months after at least two years of first-line CDK4/6 inhibitor plus aromatase inhibitor therapy; enrollment requires no detectable circulating tumor DNA at baseline.
Register Investigator Interest
Interested in offering this trial to suitable patients?